Skip to content
naulon
Not checkedNot checked for notices yet.

A superior drug carrier – aponeocarzinostatin in partially unfolded state fully protects the labile antitumor enediyne

Huang Chiy-Mey, Kumar Thallapuranam, Shanmuganathan Aranganathan and 2 more

Journal of Biomedical Science · 2009

doi:10.1186/1423-0127-16-48 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

<p>Abstract</p> <p>Background</p> <p>Neocarzinostatin is a potent antitumor drug consisting of an enediyne chromophore and a protein carrier.</p> <p>Methods</p> <p>We characterized an intermediate in the equilibrium unfolding pathway of aponeocarzinostatin, using a variety of biophysical techniques including 1-anilino-8-napthalene sulfonate binding studies, size-exclusion fast protein liquid chromatography, intrinsic tryptophan fluorescence, circular dichroism, and <sup>1</sup>H-<sup>15</sup>N heteronuclear single quantum coherence spectroscopy.</p> <p>Results</p> <p>The partially unfolded protein is in molten globule-like state, in which ~60% and ~20% tertiary and secondary structure is disrupted respectively. Despite lacking a fully coordinated tertiary structure for assembling a functional binding cleft, the protein in molten globule-like state is still able to fully protect the labile chromophore. Titration of chromophore leads the partially denatured apoprotein to fold into its native state.</p> <p>Conclusion</p> <p>These findings bring insight into conserving mechanism of neocarzinostatin under harsh environment, where even the partially denatured apoprotein exhibits protective effect, confirming the superiority of the drug carrier.</p>

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.